Your session is about to expire
← Back to Search
ARV-471 + Anastrozole for Breast Cancer
Study Summary
This trial tests a new drug to treat breast cancer in post-menopausal women.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I haven't had any cancer except for certain skin cancers or cervical pre-cancer in the last 3 years.I have not had serious heart rhythm problems in the last 6 months.I have ongoing stomach or bowel issues, like long-term diarrhea or surgeries.I have not had major surgery within the last 4 weeks.I haven't had a major heart or blood clot issue in the last 6 months.I have had treatment for breast cancer before, including chemotherapy, hormone therapy, radiation, or surgery.My breast cancer is at a stage that can be surgically removed and I don't have cancer in both breasts.The main tumor needs to be at least 1.5 cm when checked with imaging tests.My liver disease is severe (Child Pugh B or C).Your heart's electrical activity (QTcF) is longer than 470 milliseconds.I am willing to have biopsies and surgery as part of the study.I have not received any live vaccines in the last 14 days.My breast cancer is ER positive and HER2 negative.I am a woman over 18 and have gone through menopause.I do not have any active, uncontrolled infections including HBV, HCV, HIV/AIDS.My cancer is estrogen receptor positive with at least 10% of cells affected.My cancer is not HER2 positive according to tests.I am fully active or can carry out light work.My cancer has a Ki-67 score of 5% or higher.
- Group 1: ARV-471 monotherapy
- Group 2: Anastrozole monotherapy
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is ARV-471 monotherapy a viable option for patients seeking safe treatment?
"Our team at Power assigned a score of 2 to ARV-471 monotherapy's safety due to the lack of efficacy data available, despite some indications that it is safe."
Are participants still able to join this research trial?
"As per the clinicaltrials.gov website, this clinical trial is currently recruiting participants. It was first announced on January 1st 2023 and updated most recently on January 26th of the same year."
To what extent is participation in this research project limited?
"Affirmative. Data hosted on clinicaltrials.gov attests to the fact that this medical trial is still enrolling patients, after being initially posted on January 1st of 2023 and last updated at the end of said month. 150 volunteers are sought from a single site for participation in the study."
Share this study with friends
Copy Link
Messenger